ARCHIVES

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

This article is from The Cancer Letter archive.

Vol. 18 No. 34 | September 4, 1992

Download PDF Visit The Full Archive

Related Articles

Nature Editorial Criticizes NCI PR Spending

March 15, 2013

In Brief: Cooper Resigns From DPC Board, Bettinghaus Names, Chairman; William Dewyus Leaves NCI

September 13, 1985

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

June 27, 2014

Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy

June 28, 2013

HEW Secretary Tells Ethics Board To Take Up Issue of Compensation

September 28, 1979

Advisors Clear Herceptin; Find Tamoxifen Indicated For “Short Term Risk Reduction”

September 11, 1998